year 15, Issue 2 (March-April 2021)                   Iran J Med Microbiol 2021, 15(2): 257-265 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Babaei M R, Mohammadi-Vajari M, Mohammadi-Vajari E. Coagulopathy in COVID-19 Patients and Endovascular Treatment, Reports of 4 Patients. Iran J Med Microbiol. 2021; 15 (2) :257-265
URL: http://ijmm.ir/article-1-1308-en.html
1- Assistant Professor of Radiology, Fellowship of Interventional Radiology, Department of Radiology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran
2- Radiology Resident, Department of Radiology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran , malimv71@yahoo.com
3- Medical Student, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Abstract:   (423 Views)
COVID-19 pandemic due to the respiratory infection of SARS-CoV-2 has now become a global threat. The thrombotic complications are common in COVID-19 patients which have been extensively addressed in various studies. The hemorrhagic complications, however, have received less attention. In this article, 4 cases of COVID-19 patients with hemorrhagic complications are presented.
All 4 patients were hospitalized in ICU and received routine COVID-19 treatments such as heparin prophylaxis. During hospitalization, all four patients had rectus sheath hematoma and retroperitoneal hemorrhage. They underwent embolization to control hemorrhage.
Embolization of the inferior epigastric artery and the anterior trunk of internal iliac artery was carried out under fluoroscopy-guided angiography. The active hemorrhage of the patients was controlled. Three patients recovered after the treatment and were discharged while one patient, unfortunately, died due to the severity of the pulmonary involvement, old age, and hemorrhage.
First, the hemorrhage of these patients was assigned to the hemorrhagic complications due to the use of heparin. But the hemorrhage volume was not justifiable with the symptoms and complications of prophylaxis dosage of heparin. The attention was gradually drawn to the coagulopathy of the COVID-19 patients. further investigations are required to clarify the role of effective factors and complications of coagulopathy in patients with COVID-19 and their appropriate treatment.
Full-Text [PDF 686 kb]   (137 Downloads) |   |   Full-Text (HTML)  (39 Views)  
Type of Study: Case report | Subject: Medical Virology
Received: 2021/01/3 | Accepted: 2021/03/20 | ePublished: 2021/04/14

References
1. Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483-95. [DOI:10.1016/j.molmed.2020.02.008] [PMID] [PMCID]
2. Danesh F, GhaviDel S, Piranfar V. Coronavirus: Discover the Structure of Global Knowledge, Hidden Patterns & Emerging Events. J Adv Med Biomed Res. 2020;28(130):253-64. [DOI:10.30699/jambs.28.130.253]
3. Ekpunobi N, Markjonathan I, Olanrewaju O, Olanihun D. Idiosyncrasies of COVID-19; A Review. Iran J Med Microbiol. 2020;14(3):290-6. [DOI:10.30699/ijmm.14.3.290]
4. Parvizi P, Jalilian M, Parvizi H, Amiri S, Mohammad Doust H. The COVID-19 Pandemic: Data Analysis, Impacts and Future Considerations. Iran J Med Microbiol. 2021;15(1):1-17. [DOI:10.30699/ijmm.15.1.1]
5. Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor HJTJoPAJotPSoGB, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. 2004;203(2):631-7. [DOI:10.1002/path.1570] [PMID] [PMCID]
6. Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. 2020. [DOI:10.1016/j.thromres.2020.04.013] [PMID] [PMCID]
7. Azhdeh S, Mohammadi-Vajari M-A, Khaleghi M. Mesenteric Ischemia in a Case of COVID-19. Case Reports in Clinical Practice. 2020;5(Covid-19):141-4.
8. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(9):2103-9. [DOI:10.1111/jth.14975] [PMID] [PMCID]
9. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, The Journal of the American Society of Hematology. 2020;136(4):489-500. [DOI:10.1182/blood.2020006520] [PMID] [PMCID]
10. Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, et al. Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis. 2020;29(8):104984. [DOI:10.1016/j.jstrokecerebrovasdis.2020.104984] [PMID] [PMCID]
11. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Critical Care. 2020;24(1):1-8. [DOI:10.1186/s13054-020-03077-0] [PMID] [PMCID]
12. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023-6. [DOI:10.1111/jth.14810] [PMID]
13. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Haemost. 2020;50:54-67. [DOI:10.1007/s11239-020-02134-3] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2021 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc